Tower Research Capital LLC TRC Takes $93,000 Position in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Tower Research Capital LLC TRC bought a new position in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 6,052 shares of the company’s stock, valued at approximately $93,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. R Squared Ltd purchased a new stake in shares of ClearPoint Neuro in the fourth quarter worth about $32,000. AlphaQuest LLC bought a new stake in ClearPoint Neuro in the 4th quarter worth approximately $80,000. Barclays PLC raised its holdings in shares of ClearPoint Neuro by 24.3% during the 3rd quarter. Barclays PLC now owns 5,674 shares of the company’s stock worth $64,000 after acquiring an additional 1,109 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of ClearPoint Neuro by 58.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company’s stock valued at $110,000 after acquiring an additional 3,612 shares during the last quarter. Finally, ExodusPoint Capital Management LP purchased a new position in shares of ClearPoint Neuro in the fourth quarter valued at $204,000. Institutional investors own 30.08% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. B. Riley boosted their target price on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Lake Street Capital boosted their price objective on ClearPoint Neuro from $17.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, January 21st. Finally, Stifel Nicolaus upped their price objective on ClearPoint Neuro from $19.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, April 1st.

ClearPoint Neuro Stock Down 0.5 %

CLPT stock opened at $14.18 on Friday. ClearPoint Neuro, Inc. has a twelve month low of $5.11 and a twelve month high of $19.22. The firm has a market cap of $396.76 million, a price-to-earnings ratio of -20.55 and a beta of 1.03. The business’s fifty day simple moving average is $12.85 and its two-hundred day simple moving average is $14.20.

ClearPoint Neuro (NASDAQ:CLPT) last issued its earnings results on Wednesday, February 26th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05). ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. The firm had revenue of $7.77 million for the quarter, compared to the consensus estimate of $8.23 million. Research analysts expect that ClearPoint Neuro, Inc. will post -0.66 EPS for the current year.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.